作为生物制造领域的明星企业，华熙生物横跨活性物、医药医美、功能性护肤品和食品等众多赛道。过 去一年，华熙生物一直处于聚光灯下。 在政协北京市第十四届委员会第四次会议期间，来自经济界的市政协委员、华熙生物董事长赵燕围绕生 物制造产业发展、科技成果转化以及AI与产业融合等话题，接受了北京商报记者的专访。 而面对AI时代加速到来，赵燕表示，对于生物制造行业，AI不光是赋能，更是一个产业逻辑的重塑。 未来的企业能否存活，关键在于能否真正拥抱AI。要成为幸存者，企业必须重塑自身的业务逻辑与组 织架构，并配备相应的人才。 未来的团队中，管理者的能力将体现在如何管理两类人：一类是AI智能体，另一类是具有AI原生态思 维、善于运用AI的人。 与此同时，AI也拉近了我们与欧美在生物科技领域的距离。过去在从0到1的原始创新阶段，中国与发 达国家仍存在一定差距，但AI的到来实现了某种程度的"平权化"，重塑了创新逻辑。她坚信，只要在这 个时代"被重塑"，就能带来超预期的增长。 北京商报记者 陶凤 丁宁 随着透明质酸等成熟医美生物材料的市场竞争加剧，头部企业的技术积累与长期发展路径备受关注。与 此同时，各类再生材料等新兴赛道崛起，面对 ...

从资金流向上来看，当日医疗美容板块主力资金净流出4981.38万元，游资资金净流出538.33万元，散户 资金净流入5519.71万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.17 | -0.63% | | 6.67万 | | 2120.37万 | | 300896 | 爱美客 | 138.12 | -1.56% | | 2.98万 | | 4.13亿 | | 688363 | 华熙生物 | 45.64 | -1.70% | | 2.88万 | | 1.32亿 | | 920982 | 锦波生物 | 223.85 | -1.97% | | 7323.3 | | 1.65亿 | | 代码 | 名称 | | | 主力净流入（元） 主力净占比 游资净流入（元） 游资净占比 散户净流入 (元) 散户净占比 | | | | | --- | --- | --- | --- | --- | --- ...

| | | | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | 简军 | 爱美客董事长 | | 2 | 起張 | 华熙牛物青事长 | | 3 | 严建亚 | 巨子生物青事长 | | 4 | 关晓晖 | 复星医药联席董事长 | | 5 | 刘涛 | 奥园美谷董事长 | | 6 | 申东日 | 朗姿股份董事长 | | 7 | 杨霞 | 锦波生物董事长 | | 8 | 前熔 | 美年健康董事长 | | 9 | 傅海曙 | 瑞丽矢美毒事长 | | 10 | (1) 郭振宇 | 贝泰妮青事长 | | | 接单尚明:排名不分先后,围绕专业能力、业绩表现 行业/景 | | | | 响力等维度综合评选得出。 | | 瑞财经 1月28日，由瑞财经推出的"2025年度医疗美容业十大杰出人物"榜单揭晓，华熙生物董事长赵燕 入选。 "2025年度医疗美容业十大杰出人物"榜单围绕专业能力、业绩表现、行业影响力等维度综合评选得出。 赵燕，女，1966年7月出生，生物专业本科毕业，理学学士，美国福坦莫大学工商管理硕士。2000年至 2002年任华熙昕宇投资有限公司总经理；自2003年至2019年3月任华熙 ...

Core Viewpoint - Huaxi Bio, a leading company in the biomanufacturing sector, emphasizes the importance of innovation and collaboration among research institutions, enterprises, and government to drive the development of the biomanufacturing industry and achieve market transformation [3][8]. Industry Insights - The competition in the hyaluronic acid market is intensifying, with a focus on technological accumulation and long-term development paths among leading companies [3]. - The industry is shifting from a focus on single products to systemic solutions, highlighting the need for creativity and responsible marketing practices [6]. - The current market is characterized by a lack of innovation, with many companies resorting to imitation rather than developing unique solutions [6]. Talent Development - The biomanufacturing sector requires talent with interdisciplinary knowledge, including biology, engineering, AI, and bioinformatics, to meet the demands of future industry growth [7]. - Attracting creative and self-driven talent in synthetic biology is essential, necessitating a collaborative effort from government, enterprises, and individuals [7]. Policy and Government Role - Beijing has implemented policies to accelerate the innovation and market transformation of the synthetic biology manufacturing industry, demonstrating a strong governmental commitment [8]. - Local initiatives, such as those in Changping District, aim to attract relevant enterprises and talent, creating a multi-layered support system for the industry [8]. Market Transformation Challenges - The main challenge for innovative companies is the effective market transformation of new products, often hindered by strict intellectual property protection and insufficient collaboration mechanisms with research institutions [9]. - A call for government intervention to establish rules and standards for better cooperation between researchers and enterprises is emphasized, aiming to increase the current low conversion rate of research outcomes [9]. AI's Impact on Biomanufacturing - AI is becoming a foundational capability in the biomanufacturing and biotechnology sectors, with companies needing to embrace AI to survive and thrive [10]. - The integration of AI is expected to reshape business logic and organizational structures, potentially leading to exponential growth in the industry [11]. - AI has the potential to bridge the gap between China and developed countries in the biotechnology field, facilitating innovation and enhancing data-driven decision-making [11].

作为生物制造领域的明星企业，华熙生物横跨活性物、医药医美、功能性护肤品和食品等众多赛道。过去一年，华熙生物一直处于聚光灯下。 在政协北京市第十四届委员会第四次会议期间，来自经济界的市政协委员、华熙生物董事长赵燕围绕生物制造产业发展、科技成果转化以及AI与产业融合 等话题，接受了北京商报记者的专访。 随着透明质酸等成熟医美生物材料的市场竞争加剧，头部企业的技术积累与长期发展路径备受关注。与此同时，各类再生材料等新兴赛道崛起，面对行业增 量竞争转向存量博弈，赵燕直言创新的重要性，"概念总在重演，科技永远向前，不能只是去炒一个概念"。 北京打造具有国际影响力的生物医药产业集群，创新力是核心。在专访中，赵燕不止一次提及创新成果的转化，科研院校、企业、政府多方协同缺一不可。 如何能够把高校研发从"0到1"的资源和企业真正地结合起来，形成成果转化，政府要充分发挥桥梁作用。 "我认为，未来的企业能否存活，关键在于能否真正拥抱AI。" 北京商报记者丨陶凤 丁宁 而面对AI时代加速到来，赵燕表示，对于生物制造行业，AI不光是赋能，更是一个产业逻辑的重塑。她坚信，只要在这个时代"被重塑"，就能带来超预期的 增长。 以下为北京商报 ...

证券之星消息，1月27日医疗美容板块较上一交易日下跌1.41%，*ST美谷领跌。当日上证指数报收于 4139.9，上涨0.18%。深证成指报收于14329.91，上涨0.09%。医疗美容板块个股涨跌见下表： 从资金流向上来看，当日医疗美容板块主力资金净流出4131.86万元，游资资金净流出313.41万元，散户 资金净流入4445.27万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 140.31 | -1.20% | 3.13万 | 4.39 Z | | 920982 | 锦波生物 | 228.34 | -1.31% | 5531.45 | 1.27亿 | | 688363 | 华熙生物 | 46.43 | -1.59% | 4.97万 | 2.29亿 | | 000615 | *ST美谷 | 3.19 | -2.15% | 10.89万 | 3480.46万 | | 代码 | 名称 | | | 主力净流入（元） 主力净占比 ...

编辑 | 文定 近日，一则来自淘宝店"呆瓜小伙伴"的微博在美妆圈内悄然流传。这家拥有45万粉丝、运营长达十年的个人代理老店，正式宣布将在2月底全面下架所有 商品，剩余库存正以全场7折的力度进行清仓。 近两年，从服装到美妆，一批批曾风光一时的店铺接连闭店。在平台内卷加剧、监管持续收紧、电商玩法快速迭代的多重夹击之下，电商这门生意，似乎 正变得越来越难做。 头部美妆代理店闭店 派代小编打开"呆瓜小伙伴"的店铺，发现其店内销售商品较为多样，既有珀莱雅红宝石面霜、玉泽油敏霜等知名国货美妆爆款，也有一些防晒和美妆工具 等品类，价格大多集中在几十元至百元区间，整体定位偏向平价实用派。 为保持价格吸引力，店铺还配合了平台"满200减60"、"满400减120"等促销活动。 一个值得留意的细节是，店铺中不少产品链接提供"小样装"产品，相比品牌旗舰店，这相当于为消费者提供了一个低门槛的"试用入口"，也体现出个人代 理店在货盘组织上的灵活性。不过，目前大部分商品都是售罄状态。 从数据看，这家店无疑是平台生态中的"优等生"。45.8万的粉丝数，30万+的年销量，5.0分的"宝贝质量"评分、99%的88VIP好评率，以及"小众成分护 ...

| 代码 | 名称 | | | 主力净流入（元） 主力净占比 游资净流入（元） 游资净占比 散户净流入 (元) 散户净占比 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 688363 华盛生物 | | 590.51万 | 2.01% | 1656.31万 | 5.63% | -2246.82万 | -7.64% | | 920982 锦波生物 | | -383.62万 | -1.73% | 491.75万 | 2.21% | -75.65万 | -0.34% | | 000615 *ST美谷 | | -746.45万 | -25.02% | 287.49万 | 9.63% | 458.96万 | 15.38% | | 300896 | 爱美客 | -1314.78万 | -2.68% | -1326.43万 | -2.71% | 2641.21万 | 5.39% | | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- ...

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, indicating strong performance compared to the market [2]. Core Insights - The cosmetics and medical beauty sector has outperformed the market recently, with the Shenwan Beauty Care Index rising by 2.0% from January 16 to January 23, 2026, surpassing the Shenwan A Index by 0.8 percentage points [4][5]. - December 2025 saw a significant increase in social retail sales for cosmetics, reaching 38 billion yuan, with a growth rate of 8.8%, indicating robust demand even in the off-season. The overall growth rate for Q4 was 9.9%, significantly higher than the annual growth of 5.1% for 2025, driven by promotional events like Double 11 [10][17]. - The report anticipates continued high consumer demand in Q1 2026, supported by new product launches and regulatory approvals in the medical beauty sector [10]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown strong performance, with the Shenwan Cosmetics Index increasing by 2.6% and the Shenwan Personal Care Index rising by 4.2%, both outperforming the Shenwan A Index [4][5]. Key Company Reviews - Lin Qingxuan (2657HK) is highlighted as a benchmark in the high-end domestic skincare market, with revenue projected to grow from 690 million yuan in 2022 to 1.21 billion yuan in 2024, representing a CAGR of 32.7%. The company is expected to turn a profit of 187 million yuan in 2024, a 120% increase year-on-year [11][12]. - Langzi Co., Ltd. (002612.SZ) forecasts a net profit of 900 million to 1.05 billion yuan for 2025, reflecting a year-on-year growth of 245.25% to 302.80% [4]. - Qingsong Co., Ltd. (300132.SZ) anticipates a net profit of 130 million to 165 million yuan for 2025, with a growth rate of 137.73% to 201.74% [4]. Market Trends - The report notes that the high-end skincare market is expanding, with the market size expected to reach 218.5 billion yuan by 2029. The concept of "oil-based skincare" is becoming mainstream, driving growth in the facial oil segment, which is projected to grow at a CAGR of 42.8% from 2019 to 2024 [12][14]. - E-commerce channels are increasingly important, with Lin Qingxuan achieving a 65.4% online revenue share in H1 2025, leveraging platforms like Douyin and Tmall for growth [13]. Sales Data - In December 2025, the total retail sales of cosmetics reached 38 billion yuan, with a year-on-year growth of 8.8%. The overall retail sales for cosmetics in 2025 were 465.3 billion yuan, reflecting a 5.1% increase [17][21].

| 代码 | 名称 | 主力净流入 (元) | | | | 主力净占比 游资净流入 (元) 游资净占比 散户净流入 (元) 散户净占比 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 920982 锦波生物 | | | 777.78万 | 4.57% | -145.86万 | -0.86% | 838.00 | 0.00% | | 688363 华熙生物 | | | 486.39万 | 2.47% | -2118.96万 | -10.76% | 1632.57万 | 8.29% | | 000615 *ST美谷 | | | -501.91万 | -21.98% | 111.70万 | 4.89% | 390.21万 | 17.09% | | 300896 | 爱美客 | | -567.61万 | -1.31% | -1527.19万 | -3.53% | 2094.79万 | 4.84% | 证券之星消息，1月23日医疗美容板块较上一交易日上涨1.5%，华熙生物领涨。当日上证指数报收于 4136.16，上涨0.33%。深证成指报收 ...